Lucinda Bateman

Lucinda Bateman (Cindy Bateman), MD, is an ME/CFS doctor and researcher. She founded and is Chief Medical Officer of the Bateman Horne Center of Excellence for ME/CFS and Fibromyalgia in Salt Lake City, Utah.

Dr. Bateman was one of the authors of the 2011 case definition, International Consensus Criteria, and was one of the experts on the "Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome" that was convened for the 2015 Institute of Medicine report.

Suzanne Vernon, PhD, the Research Liaison at Bateman Horne Center of Excellence works closely with Dr. Bateman on ME/CFS and fibromyalgia research.

Open Letter to The Lancet

Two open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Bateman, along with 41 colleagues in the ME/CFS field, signed the second letter.

• 10 February 2016, An open letter to The Lancet, again - Virology blog

Notable studies

• 2016, Treatment of postural orthostatic tachycardia syndrome and management of myalgic encephalomyelitis/chronic fatigue syndrome following suspected West Nile virus infection Abstract
• 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
• 2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Abstract
• 2015, Distinct plasma immune signatures in ME/CFS are present early in the course of illness FULL TEXT

  "Abstract: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is an unexplained incapacitating illness that may affect up to 4 million people in the United States alone. There are no validated laboratory tests for diagnosis or management despite global efforts to find biomarkers of disease. We considered the possibility that inability to identify such biomarkers reflected variations in diagnostic criteria and laboratory methods as well as the timing of sample collection during the course of the illness. Accordingly, we leveraged two large, multicenter cohort studies of ME/CFS to assess the relationship of immune signatures with diagnosis, illness duration, and other clinical variables. Controls were frequency-matched on key variables known to affect immune status, including season of sampling and geographic site, in addition to age and sex. We report here distinct alterations in plasma immune signatures early in the course of ME/CFS (n = 52) relative to healthy controls (n = 348) that are not present in subjects with longer duration of illness (n = 246). Analyses based on disease duration revealed that early ME/CFS cases had a prominent activation of both pro- and anti-inflammatory cytokines as well as dissociation of intercytokine regulatory networks. We found a stronger correlation of cytokine alterations with illness duration than with measures of illness severity, suggesting that the immunopathology of ME/CFS is not static. These findings have critical implications for discovery of interventional strategies and early diagnosis of ME/CFS."

• 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

  Abstract: "A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated.

• 2011, Evidence for a heritable predisposition to Chronic Fatigue Syndrome

  "BACKGROUND-Chronic Fatigue Syndrome (CFS) came to attention in the 1980s, but initial investigations did not find organic causes. Now decades later, the etiology of CFS has yet to be understood, and the role of genetic predisposition in CFS remains controversial. Recent reports of CFS association with the retrovirus xenotropic murine leukemic virus-related virus (XMRV) or other murine leukemia related retroviruses (MLV) might also suggest underlying genetic implications within the host immune system. METHODS-We present analyses of familial clustering of CFS in a computerized genealogical resource linking multiple generations of genealogy data with medical diagnosis data of a large Utah health care system. We compare pair-wise relatedness among cases to expected relatedness in the Utah population, and we estimate risk for CFS for first, second, and third degree relatives of CFS cases. RESULTS-We observed significant excess relatedness of CFS cases compared to that expected in this population. Significant excess relatedness was observed for both close (p <0.001) and distant relationships (p = 0.010). We also observed significant excess CFS relative risk among first (2.70, 95% CI: 1.56-4.66), second (2.34, 95% CI: 1.31-4.19), and third degree relatives (1.93, 95% CI: 1.21-3.07). CONCLUSIONS-These analyses provide strong support for a heritable contribution to predisposition to Chronic Fatigue Syndrome. A population of high-risk CFS pedigrees has been identified, the study of which may provide additional understanding.

Clinic location

The Bateman Horne Center 24 S. 1100 E. Suite 205 Salt Lake City, Utah 84102 1-801-359-7400

Talks & interviews

• 2016, Simple But Effective Tools for Management of ME/CFS and FM - Lucinda Bateman, MD
• 2016, BHC Wings to Fly - Dr. Bateman
• 2015, Spoonie Radio Episode 10 Guest - Dr. Lucinda Bateman - Podcast and Full Text Transcript
• 9 Sep 2014, Can ME/CFS and FM Research Help You Sleep?

Webinars

Science to patients / Wetenschap voor patienten

• 2015, 68. Introduction and diagnosis / intriductie en diagnose - Dr. Lucinda Bateman
• 2015, 69. Autoimmunity in ME/cfs / Auto-immuniteit bij ME/cvs - Dr. Lucinda Bateman
• 2015, 70. Neuroinflammation and ME/cfs / Neuro-inflammatie en ME/cvs - Dr. Lucinda Bateman
• 2015, 71. ME/cfs and the Brain/ ME/cvs en de hersenen - Dr. Lucinda Bateman
• 2015, 72. Gene-expression and exercise / gen-expressie en inspanning - Dr. Lucinda Bateman
• 2015, 73. FAQs part 1 / Veel gestelde vragen deel 1 - Dr. Lucinda Bateman
• 2015, 74. FAQs part 2 / Veel gestelde vragen deel 2 - Dr. Lucinda Bateman

Solve ME/CFS Initiative

• Apr 17, 2015 "Will SEID Diagnostic Criteria Improve Diagnosis and Treatment?"
• Nov 14, 2014 "Can ME CFS and Fibromyalgia Research Help You Sleep?"

IAMECFS Conference

• 2016, 12th International IACFS/ME Biennial Clinical and Research Conference, Emerging Science and Clinical Care, Paper presentation:Synergy Trial for CFS – a phase 2 study of low-dose methylphenidate plus mitochondrial support

Blog posts

• 17 October 2016, Pearls of Wisdom from an ME/CFS Physician, part 1
• 17 October 2016, Pearls of Wisdom from an ME/CFS Physician, part 2
• 17 October 2016, Pearls of Wisdom from a CFS Physician, part 3

Awards

• 2016, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FMS scientist, physician or healthcare worker awarded by IACFS/ME

Online presence

• PubMed - Lucinda Bateman
• Twitter
• Facebook
• Website - Bateman Horne Center
• YouTube

Learn more

• Cort Johnson - Lucinda Bateman profile
• Lucinda Bateman

See also

• Bateman Horne Center
• Suzanne Vernon

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

tachycardia An unusually rapid heart beat. Can be caused by exercise or illness. A symptom of postural orthostatic tachycardia syndrome (POTS). (Learn more: www.heart.org)

myalgic encephalomyelitis (M.E.) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

cytokine any class of immunoregulatory proteins secreted by cells, especially immune cells. Cytokines are small proteins important in cell signaling that modulate the immune system. (Learn more: me-pedia.org)

double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

phase three Last phase of clinical trials before a drug can be approved for public use. Whereas Phase one assesses basic safety, and Phase two assesses basic efficacy, Phase three uses many trial participants to fully assess both safety and efficacy, and overall benefit/risk.

Short Form 36-Item Health Survey (SF-36) - A 36-item patient-reported questionnaire, used to determine patient health status and quality of life.

etiology The cause of origin, especially of a disease.